[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its COO, CLO, Secretary and Compliance Officer on a Form 4. On 11/15/2025, the officer had 3,055 shares of common stock withheld at a price of $3.25 per share. These shares were withheld by the company to cover income tax obligations associated with the vesting of restricted stock unit awards, rather than sold in an open-market transaction. After this tax withholding, the officer beneficially owned 148,048 shares of Artiva common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bush Jennifer

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO, CLO, Secy, Compliance Off

3. Date of Earliest Transaction (Month/Day/Year)
11/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/15/2025		F		3,055(1)	D	$3.25	148,048	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Neha Krishnamohan, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artiva Biotherapeutics (ARTV) report on this Form 4?

The filing reports that an Artiva Biotherapeutics officer had 3,055 shares of common stock withheld on 11/15/2025 to satisfy income tax obligations related to the vesting of restricted stock unit awards.

Who is the reporting person in the Artiva Biotherapeutics (ARTV) Form 4 filing?

The reporting person is an officer of Artiva Biotherapeutics serving as COO, CLO, Secretary, and Compliance Officer.

Was the 3,055-share transaction for Artiva Biotherapeutics (ARTV) an open-market sale?

No. The 3,055 shares were withheld by the issuer to cover income taxes due upon the vesting of restricted stock unit awards, as stated in the explanation of responses.

What is the transaction price reported in the Artiva Biotherapeutics (ARTV) Form 4?

The shares related to the transaction were reported at a price of $3.25 per share.

How many Artiva Biotherapeutics (ARTV) shares does the officer own after this transaction?

Following the reported transaction, the officer beneficially owns 148,048 shares of Artiva Biotherapeutics common stock directly.

What does the transaction code "F" mean in the Artiva Biotherapeutics (ARTV) Form 4?

The transaction code "F" indicates that the shares were withheld by the issuer to satisfy tax withholding obligations upon the vesting of equity awards, rather than being bought or sold in the market.